Biotech Startups

0 investors

Inflammasome Therapeutics develops treatments for degenerative diseases including Alzheimer's disease, multiple sclerosis, macular degeneration, and Parkinson's disease. Its approach targets inflammasome activation as a mechanism to treat these conditions.

0 investors

InflammX Therapeutics develops Xiflam, a once-daily oral small molecule that inhibits the pathologically open Connexin43 hemichannel to modulate the NLRP3 inflammasome, targeting inflammation in retinal disease. Its lead indication is the dry form of age-related macular degeneration (dry AMD), for which there is currently no approved pharmacologic treatment.

0 investors

0 investors

0 investors

0 investors

0 investors

InGeneron develops regenerative cell therapies that use a patient's adult stem cells and other regenerative cells harvested from fat or bone marrow to treat specific injuries. The company focuses on developing FDA-approved therapies through clinical trials and research in the regenerative medicine field.

0 investors

0 investors

Inhibikase Therapeutics is a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics for pulmonary arterial hypertension (PAH). It is publicly traded on Nasdaq under the ticker IKT.

0 investors

INmune Bio is a clinical-stage biotechnology company developing immunotherapies, including XPro1595, aimed at treating neurodegenerative and psychiatric diseases through a biomarker-directed approach. The company works on translating inflammatory therapies into clinical treatments for neurologic and other diseases.

0 investors

0 investors

0 investors

0 investors

0 investors

0 investors

0 investors

0 investors

0 investors

0 investors

0 investors

Innovotex develops macrocycle-mediated targeted delivery systems for cancer therapies, building multi-modal platforms intended to improve the effectiveness of targeted cancer treatments. The company operates in oncology-focused therapeutics.

0 investors

0 investors

0 investors